Current Active Clinical Trials:
Trial 1: A Multicenter, Double-Masked, Randomized, Dose Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration
Objective: The purpose of this clinical study is to evaluate the effectiveness and safety of 0.5 mg and 1.0 mg dose levels of conbercept intravitreal (IVT) injection as compared to the approved VEGF antagonist active control, aflibercept intravitreal (IVT) injection (2.0 mg/eye, Eylea® , Regeneron Pharmaceuticals, Inc. and Bayer AG) in subjects with neovascular AMD (wet AMD).
Trial 2: Randomized Trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema (Protocol AC)
Objective: To compare the efficacy of intravitreous aflibercept (Eylea) with intravitreous bevacizumab (Avastin) + deferred aflibercept if needed in eyes with Centrally-Involved Diabetic Macular Edema and moderate vision loss.
Trial 3: Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction (Protocol AG)
Objective: To compare the proportion of eyes with foveal VMT release on OCT after pneumatic vitreolysis with gas injection versus observation (sham injection) in eyes with VMT without an associated macular hole.
Trial 4: Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH)
Objective: To obtain estimates of the proportion of eyes with Macular Hole closure of the inner retinal layers for eyes with Vitreomacular Traction (VMT) and full-thickness Macular Holes treated with Pneumatic Vitreolysis (PVL).
If you have any questions or want to learn more about the current ongoing trials, please fill out the form below or call our office at 818-552-5040/310-659-2200 and speak with our Clinical Research Coordinator, Fadi Shaya.